Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems
- 1 January 2006
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 38 (3) , 162-172
Abstract
Antiplatelet therapy has been established as a preventive medicine for ischemic cardiovascular diseases both at acute and chronic phases. This therapy is also crucial for the prevention of thrombotic events after coronary stent implantation. So far, many lines of clinical evidence have demonstrated the beneficial effects of aspirin (an irreversible cyclooxygenase inhibitor) and thienopyridine derivatives (adenosine diphosphate (ADP)-receptor P2Y12 inhibitors). Recently, it has been reported that the cardiovascular risk is elevated in patients with platelets resistant to these drugs, compared to the good responders. One of the current problems to be solved in antiplatelet therapy is to find out patients resistant to the antiplatelet therapy and improve its preventive effects. In addition to aspirin and thienopyridines, several types of drugs with antiplatelet effects are currently available in clinical practice. Clinical evidence has recently been accumulating for these drugs that can be potential alternatives in patients with aspirin or thienopyridine resistance. In this review, the mechanisms, evidence and approach to the present problems of drugs with antiplatelet effects are discussed.Keywords
This publication has 77 references indexed in Scilit:
- Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesisTrends in Pharmacological Sciences, 2005
- Biological Assessment of Aspirin Efficacy on Healthy IndividualsStroke, 2005
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Sarpogrelate: cardiovascular and renal clinical potentialExpert Opinion on Investigational Drugs, 2004
- Cochrane Review: Dipyridamole for Preventing Major Vascular Events in Patients With Vascular DiseaseStroke, 2003
- Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular DiseaseCirculation, 2002
- Functional Significance of Adenosine 5′-Diphosphate Receptor (P2Y 12 ) in Platelet Activation Initiated by Binding of von Willebrand Factor to Platelet GP Ibα Induced by Conditions of High Shear RateCirculation, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- A Randomized Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk PatientsNew England Journal of Medicine, 1989